Obefazimod (ABX464)
Ulcerative Colitis
About Abivax
Abivax is a biopharmaceutical company focused on developing first-in-class therapies for inflammatory diseases and viral infections. Their lead candidate obefazimod represents a novel mechanism targeting RNA splicing to modulate immune responses. The company is publicly traded and has advanced multiple programs into clinical development, with a primary focus on inflammatory bowel disease and other immune-mediated disorders.
View full company profileAbout Abivax
Abivax is a biopharmaceutical company focused on developing first-in-class therapies for inflammatory diseases and viral infections. Their lead candidate obefazimod represents a novel mechanism targeting RNA splicing to modulate immune responses. The company is publicly traded and has advanced multiple programs into clinical development, with a primary focus on inflammatory bowel disease and other immune-mediated disorders.
View full company profileAbout Abivax
Abivax is a biopharmaceutical company focused on developing first-in-class therapies for inflammatory diseases and viral infections. Their lead candidate obefazimod represents a novel mechanism targeting RNA splicing to modulate immune responses. The company is publicly traded and has advanced multiple programs into clinical development, with a primary focus on inflammatory bowel disease and other immune-mediated disorders.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Mirikizumab | Eli Lilly | Phase 3 |
| Filgotinib | Gilead Sciences | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 3 |
| DE-130 (Etrasimod) | Rohto Pharmaceutical | Phase 3 |
| DE-122 (Carotegrast methyl) | Rohto Pharmaceutical | Phase 3 |
| Methylene Blue MMX® | Cosmo Pharmaceuticals | Preclinical |
| KRP-203 (Amiselimod) | Kissei Pharmaceutical | Phase II |
| EVO301 | Evommune | Phase 1 |
| Pentasa (Mesalazine) | Zeria Pharmaceutical | Approved/Commercial |
| SER-301 | Seres Therapeutics | Phase 1b |
| SER-287 | Seres Therapeutics | Phase 2b |
| IMP731 | Immutep | Phase 2 |